HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death

Current Medicinal Chemistry

Volumn 20, Issue 38, 2013, Pages 4815-4826

  Sirova, M ^a   Kabesova, M ^a   Kovar, L ^a   Etrych, T ^b   Strohalm, J ^b   Ulbrich, K ^b   Rihova, B ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Anti tumor immune response; Calreticulin; Heat shock proteins; HMGB1; HPMA based doxorubicin delivery; Targeted cytotoxic drugs

Indexed keywords

AMIDE; B7 ANTIGEN; CALRETICULIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD47 ANTIGEN; CD86 ANTIGEN; CHAPERONIN 60; COPOLYMER; DOXORUBICIN; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN-N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER CONJUGATE; DRUG CARRIER; HEAT SHOCK PROTEIN; POLYMETHACRYLIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CANCER SURVIVOR; CELL DEATH; CELL LYSATE; CELL MATURATION; CELL SURFACE; CONTROLLED STUDY; COVALENT BOND; DENDRITIC CELL; DRUG CONJUGATION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTOXICITY; INCUBATION TIME; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX TYPE II; MONONUCLEAR CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PH; PHAGOCYTOSIS; PROTEIN SECRETION; SPLEEN CELL; T CELL LYMPHOMA; TARGET CELL; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR RESISTANCE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; LYMPHOMA, T-CELL; METABOLISM; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALRETICULIN; CELL LINE, TUMOR; DENDRITIC CELLS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HEAT-SHOCK PROTEINS; HMGB1 PROTEIN; HYDROGEN-ION CONCENTRATION; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; POLYMETHACRYLIC ACIDS;

EID: 84889582173     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660281     Document Type: Article

References (44)

1. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Andre, F.; Tesniere, A.; Kroemer, G. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest., 2008, 118(6), 1991-2001. (Pubitemid 351872317)
2. Rihova, B.; Kovar, M. Immunogenicity and immunomodulatory properties of HPMA-based polymers. Adv. Drug Deliv. Rev., 2010, 62(2), 184-191.
3. Etrych, T.; Strohalm, J.; Chytil, P.; Rihova, B.; Ulbrich, K. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors. J. Drug Target., 2011, 19(10), 874-89.
4. Kopecek, J.; Kopeckova, P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev., 2010, 62(2), 122-49.
5. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem., 2010, 21(5), 797-802.
6. Mrkvan, T.; Sirova, M.; Etrych, T.; Chytil, P.; Strohalm, J.; Plocova, D.; Ulbrich, K.; Rihova, B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor imunity. J. Control. Release, 2005, 110(1), 119- 129. (Pubitemid 41713936)
7. Sirova, M.; Strohalm, J.; Subr, V.; Plocova, D.; Rossmann, P.; Mrkvan, T.; Ulbrich, K.; Rihova, B. Treatment with HPMA copolymer- based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol. Immunother., 2007, 56(1), 35-47. (Pubitemid 44812445)
8. Kovar, M.; Tomala, J.; Chmelova, H.; Kovar, L.; Mrkvan, T.; Joskova, R.; Zakostelska, Z.; Etrych, T.; Strohalm, J.; Ulbrich, K.; Sirova, M.; Rihova, B. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1- specific resistance in mice cured by targeted polymer-bound doxorubicin. Cancer Res., 2008, 68(23), 9875-83.
9. Etrych, T.; Sirova, M.; Starovoytova, L.; Rihova, B.; Ulbrich, K. HPMA copolymer conjugates of paclitaxel and docetaxel with pHcontrolled drug release. Mol. Pharm., 2010, 7(4), 1015-26.
10. Choi, W. M.; Kopeckova, P.; Minko, T.; Kopecek, J. Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells. J. Bioact. Compat. Pol., 1999, 14(6), 447-456.
11. Etrych, T.; Jelinkova, M.; Rihova, B.; Ulbrich, K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release, 2001, 73(1), 89-102. (Pubitemid 32406104)
12. Rihova, B.; Etrych, T.; Pechar, M.; Jelinkova, M.; Stastny, M.; Hovorka, O.; Kovar, M.; Ulbrich, K. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J. Control. Release, 2001, 74(1-3), 225-232. (Pubitemid 32727624)
13. Kopecek, J.; Kopeckova, P.; Minko, T.; Lu, Z. HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm., 2000, 50(1), 61-81. (Pubitemid 30326689)
14. Hovorka, O.; St'astny, M.; Etrych, T.; Subr, V.; Strohalm, J.; Ulbrich, K.; Rihova, B. Differences in the intracellular fate of free and polymer-bound doxorubicin. J. Control. Release, 2002, 80(1- 3), 101-117. (Pubitemid 34273752)
15. Hovorka, O.; Etrych, T.; Subr, V.; Strohalm, J.; Ulbrich, K.; Rihova, B. HPMA based macromolecular therapeutics: Internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and also on spacer composition. J. Drug Target., 2006, 14(6), 391-403. (Pubitemid 44203519)
16. Ríhová, B.; Strohalm, J.; Hovorka, O.; Subr, V.; Etrych, T.; Chytil, P.; Pola, R.; Plocová, D.; Boucek, J.; Ulbrich, K. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMAbased pharmaceuticals: In vitro effect of extra drug-free Gly- PheLeuGly sequences. J. Control. Release, 2008, 127(2), 110-120.
17. Seymour, L. W.; Miyamoto, Y.; Maeda, H.; Brereton, M.; Strohalm, J.; Ulbrich, K.; Duncan, R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer, 1995, 31A(5), 766-770.
18. Lammers, T.; Kuhnlein, R.; Kissel, M.; Subr, V.; Etrych, T.; Pola, R.; Pechar, M.; Ulbrich, K.; Storm, G.; Huber, P.; Peschke, P. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J. Control. Release, 2005, 110(1), 103-118. (Pubitemid 41713935)
19. Rihova, B.; Kovar, L.; Kovar, M.; Hovorka, O. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics. Trends Biotechnol., 2009, 27(1), 11-17.
20. Ma, Y.; Conforti, R.; Aymeric, L.; Locher, C.; Kepp, O.; Kroemer, G.; Zitvogel, L. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev., 2011, 30(1), 71-82.
21. Frey, B.; Rubner, Y.; Wunderlich, R.; Weiss, E. M.; Pockley, A. G.; Fietkau, R.; Gaipl, U. S. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr. Med. Chem., 2012, 19(12), 1751-1764.
22. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G. M.; Apetoh, L.; Perfettini, J.-L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med., 2007, 13(1), 54-61. (Pubitemid 46067386)
23. Zitvogel, L.; Kepp, O.; Senovilla, L.; Menger, L.; Chaput, N.; Kroemer, G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res., 2010, 16(12), 3100-3104.
24. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J. P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 2007, 13(9), 1050-1059. (Pubitemid 47517504)
25. Spisek, R.; Charalambous, A.; Mazumder, A.; Vesole, D. H.; Jagannath, S.; Dhodapkar, M. V. Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood, 2007, 109(11), 4839-4845. (Pubitemid 46827780)
26. Apetoh, L.; Mignot, G.; Panaretakis, T.; Kroemer, G.; Zitvogel, L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol. Med., 2008, 14(4), 141-151.
27. Casares, N.; Pequignot, M. O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M.; Coutant, F.; Metivier, D.; Pichard, E.; Aucouturier, P.; Pierron, G.; Garrido, C.; Zitvogel, L.; Kroemer, G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med., 2005, 202(12), 1691-1701. (Pubitemid 41815875)
28. Fucikova, J.; Kralikova, P.; Fialova, A.; Brtnicky, T.; Rob, L.; Bartunkova, J.; Spisek, R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res., 2011, 71(14), 4821-4833.
29. Messmer, D.; Yang, H.; Telusma, G.; Knoll, F.; Li, J.; Messmer, B.; Tracey, K. J.; Chiorazzi, N. High Mobility Group Box Protein 1: An Endogenous Signal for Dendritic Cell Maturation and Th1 Polarization. J. Immunol., 2004, 173(1), 307-313. (Pubitemid 38797355)
30. Ulbrich, K.; Subr, V.; Strohalm, J.; Plocova, D.; Jelinkova, M.; Rihova, B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J. Control. Release, 2000, 64(1-3), 63-79. (Pubitemid 30035308)
31. Etrych, T.; Mrkvan, T.; Chytil, P.; Konak, C.; Rihova, B.; Ulbrich, K. Polymer prodrugs based on HPMA conjugates with pHcontrolled activation of doxorubicin: I. Synthesis, physicochemical characterisation and preliminary biological evaluation. J. Appl. Polym. Sci., 2008, 109, 3050-3061.
32. Rejmanova, P.; Labsky, J.; Kopecek, J. Aminolyses of monomeric and polymeric 4-nitrophenyl esters of Nmethacryloylated amino acids. Makromol. Chem., 1977, 178, 2159-2168.
33. Rihova, B.; Bilej, M.; Vetvicka, V.; Ulbrich, K.; Strohalm, J.; Kopecek, J.; Duncan, R. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials, 1989, 10(5), 335-342. (Pubitemid 19174801)
34. Rihova, B.; Kopeckova, P.; Strohalm, J.; Rossmann, P.; Vetvicka, V.; Kopecek, J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol., 1988, 46(1), 100-114. (Pubitemid 18052006)
35. Ríhová, B.; Strohalm, J.; Kubácková, K.; Jelínková, M.; Hovorka, O.; Kovár, M.; Plocová, D.; Sírová, M.; St'astný, M.; Rozprimová, L.; Ulbrich, K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Control. Release, 2002, 78(1-3), 97-114. (Pubitemid 34081856)
36. Ríhová, B.; Strohalm, J.; Prausová, J.; Kubácková, K.; Jelínková, M.; Rozprimová, L. k.; Sírová, M.; Plocová, D.; Etrych, T.; Subr, V.; Mrkvan, T.; Kovár, M.; Ulbrich, K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release, 2003, 91(1-2), 1-16. (Pubitemid 37288875)
37. Rihova, B. Clinical experience with anthracycline antibiotics- HPMA copolymer-human immunoglobulin conjugates. Adv. Drug Deliv. Rev., 2009, 61(13), 1149-1158.
38. Panaretakis, T.; Joza, N.; Modjtahedi, N.; Tesniere, A.; Vitale, I.; Durchschlag, M.; Fimia, G. M.; Kepp, O.; Piacentini, M.; Froehlich, K. U.; van Endert, P.; Zitvogel, L.; Madeo, F.; Kroemer, G. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ., 2008, 15(9), 1499- 1509.
39. Panaretakis, T.; Kepp, O.; Brockmeier, U.; Tesniere, A.; Bjorklund, A. C.; Chapman, D. C.; Durchschlag, M.; Joza, N.; Pierron, G.; van Endert, P.; Yuan, J.; Zitvogel, L.; Madeo, F.; Williams, D. B.; Kroemer, G. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO. J., 2009, 28(5), 578-590.
40. Obeid, M. ERP57 Membrane Translocation Dictates the Immunogenicity of Tumor Cell Death by Controlling the Membrane Translocation of Calreticulin. J. Immunol., 2008, 181(4), 2533-2543.
41. Dai, J.; Liu, B.; Caudill, M. M.; Zheng, H.; Qiao, Y.; Podack, E. R.; Li, Z. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun., 2003, 3, 1.
42. Gardai, S. J.; McPhillips, K. A.; Frasch, S. C.; Janssen, W. J.; Starefeldt, A.; Murphy-Ullrich, J. E.; Bratton, D. L.; Oldenborg, P. A.; Michalak, M.; Henson, P. M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell, 2005, 123(2), 321-334. (Pubitemid 41457220)
43. Schildkopf, P.; Frey, B.; Ott, O. J.; Rubner, Y.; Multhoff, G.; Sauer, R.; Fietkau, R.; Gaipl, U. S. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother. Oncol., 2011, 101(1), 109-115.
44. Rihova, B. Biocompatibility and immunocompatibility of watersoluble polymers based on HPMA. Composites: Part B, 2007, 38, 386-397. (Pubitemid 46149463)